Boehringer Ingelheim has signed a new digital health deal that it hopes will help with aimed adherence and care management for people living with COPD and asthma.
The firm says its US deal with Propeller Health is the first commercial partnership of its kind in respiratory medicine.
The deal will see people living with COPD and asthma and treated with a Boehringer medication that can be used in its Respimat inhaler offered the opportunity to enrol – via select US health systems – in a new programme.
This is designed to determine how Propeller’s novel health technology tool for the Respimat inhaler impacts adherence rates and patient engagement.
Propeller uses a combination of inhaler sensors, apps, analytics, personal feedback and education to passively track how patients use inhaled medications.
Ruchin Kansal, executive director and head, business innovation at Boehringer Ingelheim Pharmaceuticals, said: “Boehringer Ingelheim is proud to embark on this industry-leading partnership with Propeller with the goal of improving the care of people living with COPD and asthma.”
